Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × NSCLC × Axitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 31 Kidney Neoplasms 9 Neoplasm Metastasis 6 Melanoma 5 Neoplasms 4 Glioblastoma 4 Colorectal Neoplasms 4 Carcinoma, Hepatocellular 4 Recurrence 3 Clear-cell metastatic renal cell carcinoma 3 Sarcoma 2 Liver Neoplasms 2 Endometrial Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 cT2a N0NxM0 Renal Tumor 1 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solitary Fibrous Tumors 1 Solid Malignancies 1 Skin Neoplasms 1 Sarcoma, Alveolar Soft Part 1 Salivary Gland Neoplasms 1 Relapsed Pediatric Solid Tumor 1 Radiation Therapy 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Neuroma, Acoustic 1 Neurofibromatosis 2 1 Neuroendocrine Tumors 1

Interventions

Drug Therapy 8 osimertinib 7 Pemetrexed 7 Radiotherapy 6 anlotinib 5 Carboplatin 5 Radiosurgery 4 Gefitinib 4 Docetaxel 4 tislelizumab 3 pembrolizumab 3 icotinib 3 aflutinib 3 Vinorelbine 3 Gemcitabine 3 Erlotinib Hydrochloride 3 Cisplatin 3 toripalimab 2 dacomitinib 2 apatinib 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2 Paclitaxel 2 Immune Checkpoint Inhibitors 2 Chemotherapy, Adjuvant 2 Chemoradiotherapy 2 Bevacizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06020352 2023-08-31

The Efficacy and Safety of KN046 Combined With Axitinib

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2/3 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡